Andere talen Cybin Inc.

Aandelen

CYBN

CA23256X1006

Beurs gesloten - Nyse Andere beurzen 22:00:00 06-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,368 ^USD	+5,14%		+5,14%	-10,24%

15/03	Sectorupdate: Aandelen gezondheidszorg vrijdagmiddag zachter	MT
15/03	Cybin start fase 2 proof-of-concept studie in gegeneraliseerde angststoornis	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	06/05
Cybin to Participate at the 27th Annual Milken Institute Global Conference	25/04
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry	18/04
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	17/04
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	16/04
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder	16/04
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	10/04
Cybin : MATERIAL CHANGE REPORT - Form 6-K	22/03
Cybin : AGENCY AGREEMENT - Form 6-K	21/03
Cybin Inc. announced that it has received $150 million in funding from a group of investors	19/03
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas	18/03
Sector Update: Health Care Stocks Softer Friday Afternoon	15/03
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	15/03
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder	15/03
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	15/03
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO	15/03
Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3	14/03
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3	14/03
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	14/03
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	14/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cybin Inc.

Aandelen

CYBN

CA23256X1006

Andere talen

Filters